Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform

Core Viewpoint - Glucotrack, Inc. has received three patents for its continuous blood glucose monitoring (CBGM) platform, enhancing its competitive position and intellectual property protection as it moves towards commercialization of its fully implantable system [1][4]. Patent Details - The patents cover essential technologies in Glucotrack's CBGM system, including proprietary sensor chemistry, intravascular lead design, and low-power electronics [2]. - The patents issued are US 12,453,494, US 12,458,257, and US 12,458,258, which focus on improving glucose measurement methods and sensor design [9]. Product Features - Glucotrack's CBGM is designed for long-term implantation, with a sensor longevity of up to three years and no wearable components, providing a more convenient glucose monitoring solution [4][6]. - The system measures glucose directly from blood, aiming to deliver real-time readings without the lag associated with traditional interstitial fluid measurements [4]. Strategic Importance - Securing these patents is a significant milestone for Glucotrack, as it establishes competitive barriers and strengthens the company's position in the diabetes management market [4].